Bartosz Puła/LinkedIn
Oct 31, 2026, 10:54
Bartosz Puła: New Advances in Hematology Featured in Acta Haematologica Polonica
Bartosz Puła, Associate Professor at Medical University of Lodz, shared a post on LinkedIn:
“The new issue of Acta Haematologica Polonica is now available
As Editor-in-Chief, I invite you to explore Volume 57, Number 5. This issue brings together original Polish clinical research and focused reviews addressing targeted therapy, transplantation, CAR T-cell therapy, hemophilia, and the molecular biology of hematologic malignancies.
The issue includes:
- Preliminary report on prophylaxis with emicizumab in Polish infants with hemophilia A
Early Polish multicenter experience suggests fewer treated bleeding episodes, with no intracranial hemorrhage or adverse events reported during short-term follow-up. - The impact of proteinuria in allogeneic hematopoietic cell transplant recipients: a single center study employing urine protein electrophoresis
Proteinuria between days 8 and 21 after allo-HCT was associated with severe acute GvHD, supporting further evaluation of urinary protein electrophoresis. - Allogeneic stem cell transplantation remains an effective therapeutic option for patients with relapsed/refractory Hodgkin lymphoma: a Polish single-center retrospective analysis
In 24 patients, estimated two-year overall and progression-free survival both reached 83.3 percent, with acceptable toxicity. - Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review
A practice-oriented overview of approved BCMA-directed products, long-term outcomes, late toxicities, post-BCMA sequencing and emerging platforms. - Autophagy in myeloid neoplasms: what is there to discuss?
The review examines autophagy’s dual role in AML, MDS, and myeloproliferative neoplasms, including its contribution to treatment resistance. - Pirtobrutinib in the Bruton tyrosine kinase landscape in chronic lymphocytic leukemia: incremental advance or new standard?
A detailed assessment of pharmacology, clinical efficacy, safety, resistance and the evolving position of pirtobrutinib in CLL sequencing. - EZH2 mutations and their importance in hematologic disorders: from diagnostics to new treatment strategies
The authors connect molecular diagnostics and liquid biopsy with EZH2 inhibitors, dual EZH1/2 inhibition, PROTACs and gene-editing strategies. - Analysis of mechanisms increasing the risk of inhibitor development during hemophilia A treatment
A review of the genetic, immune and treatment-related determinants of factor VIII inhibitor formation and emerging therapeutic approaches. - A rare case of secondary cerebrospinal fluid involvement by extranodal marginal zone lymphoma of the salivary gland diagnosed in a paucicellular sample by flow cytometry
The report highlights the diagnostic value of flow cytometry when conventional CSF cytology is inconclusive.
Stay updated with Hemostasis Today.
-
Oct 31, 2026, 12:21Niksa Bagheri: Key Shear Regimes and Physics Selection for Continuum Thrombosis Modeling
-
Oct 31, 2026, 12:14Ghaith Abu-Zeinah: International MPN Congress Honors the Life and Legacy of MPN Pioneer Dr. Richard T. Silver
-
Oct 31, 2026, 12:11Thierry Burnouf: Taipei Medical University and University of Lille Highlight Platelet Biotherapies in SfN Neuronline
-
Oct 31, 2026, 12:07Eamon Faulkner: How Oxygen Shapes Platelet–Endothelial Interactions
-
Oct 31, 2026, 12:01Abdul Mannan: IVIG in ITP – When a Temporary Response Is a Success
-
Oct 31, 2026, 11:52Breaking the Silence Around Bleeding Disorders in Women – National Bleeding Disorders Foundation
-
Oct 31, 2026, 11:21Jim Meliezer: Aspirin May Help Prevent Recurrent Preterm Birth
-
Oct 31, 2026, 11:10Elly De Bruyn: QbD Group Quiz Supports the World Federation of Hemophilia
-
Oct 31, 2026, 11:04Abhivandan Nagia: The Expanding Clinical Pipeline in Hemophilia A